

August 25, 2025

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai 400001  
**Stock Code: 532504**

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai 400051  
**Stock Code: NAVINFLUOR**

Dear Sir / Madam,

**Sub.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you as under:

- 1) Mr. Rajendra Sahu, CEO – CDMO Business, has tendered his resignation to pursue career prospects elsewhere, and as such, will be relieved from the services of the Company effective from the close of business hours of September 20, 2025. Please find enclosed **Annexure A** in this regard.
- 2) Dr. Vijay Kaiwar has been appointed by the Company w.e.f. today and is designated as CEO Designate of CDMO Business. He will assume responsibilities as CEO of our CDMO Business w.e.f. September 21, 2025. Brief Profile of Dr. Kaiwar is enclosed as **Annexure B**.

This intimation is also being made available on the Company's website [www.nfil.in](http://www.nfil.in)

This is for your information and record.

Thanking You,  
Yours faithfully,

For **NAVIN FLUORINE INTERNATIONAL LIMITED**

**Niraj B. Mankad**  
**President Legal and Company Secretary**

*Encl.: a/a*

Annexure A

To,

Mr. Nitin Kulkarni  
The Managing Director  
Navin Fluorine International Limited

From,

Rajendra Kumar Sahu  
CEO- CDMO Division

Date: 1<sup>st</sup> Aug 2025

Dear Sir,

I am writing to inform you of my resignation as CEO of CDMO business for better prospect. It has been my privilege to serve this great company with such a prodigious legacy for more than 5 years and am proud of the progress we have made during my tenure. Under my leadership, Navin Molecular has become one of the prominent players in the Pharma CDMO industry, with a strong reputation for innovation, complex chemistries and quick customer service. We have grown our market to other geographies, increased our profitability, and expanded our product line at its' best. I am pleased of the contributions I have made to the company, and confident that the business is well-positioned for continued success in the future. I would like to thank Navin Family and the Board members for their unwavering support for this business to grow it to next level.

I am writing to express my deepest gratitude to our esteemed Chairman Vishad Sir for his inspiring leadership, continuous support and guidance to me during my tenure in this organisation.

Request you to relieve me from close of business hour of 20<sup>th</sup> Septemeber,2025.

Thank you once again and I wish the Company (NFIL) all the best in the exciting journey.

Your Sincerely



Rajendra Kumar Sahu

## Annexure B

### **Brief Profile of Mr. Vijay Kaiwar:**

Dr. Vijay Kaiwar brings with him nearly 30 years of rich experience in CDMO and API businesses, specializing in Chemistry and Biotechnology with leadership exposure across multiple functions, including R&D, Technology Transfer, Operations, Projects, Manufacturing, EHS, and Business Development.. He has held senior leadership roles at Anthem Biosciences, Sun Pharma, Aurobindo Pharma, and Jubilant Organosys, where he led high-performing CDMO teams delivering innovative solutions to global pharmaceutical clients. Earlier in his career, he has also worked at Atul Limited.

Over the years, Dr. Kaiwar has built strong partnerships with leading pharma and biotech companies globally, supporting the development and commercial manufacturing of products across clinical and commercial phases. His expertise spans regulatory affairs and a broad spectrum of technologies, including small and large molecules, peptides, HPAPIs, ADCs, oligonucleotides, fermentation, probiotics, and more.

Dr. Kaiwar holds a Ph.D. in Organic Chemistry from IICT Hyderabad as also, a Post-Doctoral Fellowship from King's College, London.